Clin2
NCT06670209Possibly a fitNot yet recruiting

Drug interaction study for weight management medication

Type 2 Diabetes

Part of Hormones & metabolism clinical trials.

This study tests how a new injectable weight loss drug affects the way the body processes metformin, a common diabetes medication. It is for Chinese adults who are overweight or obese.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
32 people
Ages
18 years to 50 years
Study type
Interventional

Who can take part

  • You are Chinese, overweight or obese, and willing to have injections.
  • You are between 18 and 50 years old.
  • You weigh at least 50 kg, with a BMI between 24 and 33.
  • You are able to follow study rules and understand possible side effects.
  • You agree to use birth control and not plan pregnancy or sperm/egg donation for 3 months after the last dose.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06974487Not yet recruiting· Phase 1
Study of GZR102, GZR4, and GZR18 injections in overweight adults

This trial tests a new injection (GZR102) compared to two other injections (GZR4 and GZR18) in overweight adults. The goal is to see how well the body processes each drug and their effects. It may help researchers find a better treatment for weight management.

Beijing
NCT07550816Recruiting· Phase 1
Safety study of ZT002 injection in overweight adults

This study tests how a new diabetes medicine called ZT002 works in the body and whether it interacts safely with other common medications. Researchers will monitor healthy volunteers who are overweight to understand the medicine's safety and effectiveness.

Chengdu, Sichuan
NCT07785934Recruiting· Phase 1
Testing a new weight management injection for drug interactions

This study tests a new injectable medication for weight management in people with overweight or obesity. It investigates how the drug interacts with other medications and checks its safety. Participation requires a 6-month commitment with regular study visits.

Hefei, Anhui
NCT07128888Recruiting· Phase 1
GZR18 injection effects on stomach emptying and drug interactions

This trial tests how a new injectable drug, GZR18, affects how fast your stomach empties and how it interacts with other medicines. It is for obese Chinese adults who want to join a research study.

Beijing
NCT07355738Recruiting· Phase 1
Bioequivalence study of GZR18 injection

This study tests whether a change in the manufacturing process for GZR18 (an experimental injectable drug) affects how it works in the body. It may help determine if the new version is as safe and effective as the original.

Suzhou, Suzhou
NCT06924320Recruiting· Phase 1/Phase 2
Study of two medicines for weight loss and diabetes

This study tests two investigational medications, MET233 and MET097, in people with obesity or overweight, with or without type 2 diabetes. It aims to see if the combination can help with weight loss and blood sugar control.

Cypress, California

Hear when a new Type 2 diabetes trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.